Evidence and interdisciplinary consensus-based German guidelines: Surgical treatment and radiotherapy of melanoma

Melanoma Research

Volumn 18, Issue 1, 2008, Pages 61-67

  Garbe, Claus ^a   Hauschild, Axel ^b   Volkenandt, Matthias ^c   Schadendorf, Dirk ^d   Stolz, Wilhelm ⁱ   Reinhold, Uwe ^j   Kortmann, Rolf Dieter ^k   Kettelhack, Christoph ⁿ   Frerich, Bernhard ^k   Keilholz, Ulrich ^l   Dummer, Reinhard ^o   Sebastian, Günther ^e   Tilgen, Wolfgang ^f   Schuler, Gerold ^g   MacKensen, Andreas ^m   Kaufmann, Roland ^h  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c University Department of Neurology   (Germany)

^d University Department of Dermatology   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ University Medical Center ^*  (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁿ Departments of Surgery   (Switzerland)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Consensus based; Evidence; German; Guidelines; Interdisciplinary; Melanoma; Radiotherapy; Surgical treatment

Indexed keywords

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; DISTANT METASTASIS; EVIDENCE BASED PRACTICE; GERMANY; HUMAN; HYPERTHERMIC THERAPY; INTERDISCIPLINARY RESEARCH; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SENTINEL LYMPH NODE; SKIN METASTASIS; TUMOR VOLUME; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; SKIN TUMOR;

COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; MELANOMA; SKIN NEOPLASMS;

EID: 42449083832     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f0c893     Document Type: Article

References (73)

1. Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002; 46:690-694.
2. Hauschild A, Eiling S, Lischner S, Haacke TC, Christophers E. Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials. Hautarzt 2001; 52:1003-1010.
3. Breuninger H, Kettelhack C. Therapy of primary and metastasized melanoma. Onkologie 2001; 7:36-43.
4. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, et al. UK guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146:7-17.
5. Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579-586.
6. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262-267.
7. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998; 5:322-328.
8. O'Rourke MG, Altmann CR. Melanoma recurrence after excision. Is a wide margin justified? Ann Surg 1993; 217:2-5.
9. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996; 77:1809-1814.
10. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126:438-441.
11. Kaufmann R, Tilgen W, Garbe C. Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V. Hautarzt 1998; 48 (Suppl 1):S30-S38.
12. Kaufmann R. Surgical management of primary melanoma. Clin Exp Dermatol 2000; 25:476-481.
13. Breuninger H, Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. J Pathol 1988; 154:167-171.
14. Breuninger H, Schlagenhauff B, Stroebel W, Schaumburg-Lever G, Rassner G. Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. Am J Surg Pathol 1999; 23:1493-1498.
15. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146:1042-1046.
16. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351:793-796.
17. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of lymphatic mapping fpr early stage melanoma. Arch Surg 1992; 127:392-399.
18. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
19. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89:236-241.
20. Cochran AJ. The pathologist's role in sentinel lymph node evaluation. Semin Nucl Med 2000; 30:11-17.
21. McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86:212-223.
22. Lin D, Franc BL, Kashani-Sabet M, Singer MI. Lymphatic drainage patterns of head and neck cutaneous melanoma observed on lymphoscintigraphy and sentinel lymph node biopsy. Head Neck 2006; 28:249-255.
23. Chao C, Wong SL, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol 2003; 10:21-26.
24. Medina JE, Ferlito A, Brandwein MS, Fisher SR, Pellitteri PK, Shaha AR, et al. Current management of cutaneous malignant melanoma of the head and neck. Acta Otolaryngol 2002; 122:900-906.
25. Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G. Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001; 203:75-80.
26. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001; 19:2851-2855.
27. Thoma JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma. BMJ 2000; 321:3-4.
28. Thomas JM. Time for comprehensive reporting of MSLT-I. Lancet Oncol 2006; 7:9-11.
29. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, Morton DL. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999; 6:442-449.
30. Wagner JD, Davidson D, Coleman JJ III, Hutchins G, Schauwecker D, Park HM, Havlik RJ. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol 1999; 6:398-404.
31. Wagner JD, Gordon MS, Chuang TY, Coleman JJ III, Hayes JT, Jung SH, Love C. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89:453-462.
32. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991; 214:627-636.
33. Karakousis CP, Emrich LJ, Driscoll DL, Rao U. Survival after groin dissection for malignant melanoma. Surgery 1991; 109:119-126.
34. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214:491-499.
35. Chan AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg 2000; 191:16-22.
36. White RR, Stanley WE, Johnson JL, Tyler D, Seigler HF. Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002; 235:879-887.
37. Byers RM. Treatment of the neck in melanoma. Otolaryngol Clin North Am 1998; 31:833-839.
38. Schmalbach CE, Johnson TM, Bradford CR. The management of head and neck melanoma. Curr Probl Surg 2006; 43:781-835.
39. Mack LA, McKinnon JG. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol 2004; 86:189-199.
40. Karakousis CP, Hena MA, Emrich LJ, Driscoll DL. Axillary node dissection in malignant melanoma: results and complications. Surgery 1990; 108:10-17.
41. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma. Prognostic variables in node-positive patients. Ann Surg 1990; 212:125-131.
42. Shen P, Conforti AM, Essner R, Cochran AJ, Turner RR, Morton DL. Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer J 2000; 6:93-97.
43. Lawton G, Rasque H, Ariyan S. Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. J Am Coll Surg 2002; 195:339-351.
44. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491-502.
45. Kettelhack C, Hohenberger P, Schlag PM. Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma. Dtsch Med Wochenschr 1997; 122:177-181.
46. Brega K, Robinson WA, Winston K, Wittenberg W. Surgical treatment of brain metastases in malignant melanoma. Cancer 1990; 66:2105-2110.
47. Leo F, Cagini L, Rocmans P, Capello M, van Geel AN, Maggi G, et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000; 83:569-572.
48. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44:607-618.
49. Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88:88-94.
50. Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF. Elective radiation therapy for high-risk malignant melanomas. Cancer J 2001; 7:498-502.
51. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43:477-482.
52. Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30:795-798.
53. Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcony L, Thorpe C. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19:369-371.
54. Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatol 2001; 144:66-70.
55. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002; 52:964-972.
56. Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia C, Kraybill WG. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46:467-474.
57. Burmeister BH, Smithers BM, Davis S, Spry N, Johnson C, Krawitz H, Baumann KC. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 2002; 72:344-348.
58. Fenig E, Eidelevich E, Njuguna E, Katz A, Gutman H, Sulkes A, Schechter J. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 1999; 22:184-186.
59. Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999; 9:611-613.
60. Kortmann RD, Hoffmann W, Schiebe M, Bamberg M. Radiotherapy for treatment of tumor pain. Onkologie 1995; 1:327-334.
61. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988; 15:859-864.
62. Stevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol 1992; 23:185-191.
63. Isokangas OP, Muhonen T, Kajanti M, Pyrhonen S. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996; 38:139-144.
64. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 2002; 94:2265-2272.
65. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 2002; 29:518-524.
66. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL. Stereotactic radiosurgery for patients with 'radioresistant' brain metastases. Neurosurgery 2002; 51:656-665.
67. Chen JC, Petrovich Z, O'Day S, Morton D, Essner R, Giannotta SL, Yu C, Apuzzo ML. Stereotactic radiosurgery in the treatment of metastatic disease to the brain. Neurosurgery 2000; 47:268-279.
68. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000; 93:9-18.
69. Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L. Gamma surgery for melanoma metastases in the brain. J Neurosurg 2002; 96:544-551.
70. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003; 13:97-103.
71. Emami B, Perez CA, Konefal J, Pilepich MV, Leybovich L, Straube W, et al. Thermoradiotherapy of malignant melanoma. Int J Hyperthermia 1988; 4:373-381.
72. Engin K, Tupchong L, Waterman FM, Moylan DJ, Nerlinger RE, Leeper DB. Hyperthermia and radiation in advanced malignant melanoma. Int J Radiat Oncol Biol Phys 1993; 25:87-94.
73. Overgaard J, Gonzalez GD, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12:3-20.